Personalis (PSNL) PT Raised to $3.50 at Needham, '4Q23 Consistent with Preannouncement; Aiming for $100M of Sales in 2025'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Personalis (PSNL) PT Raised to $3.50 at Needham, '4Q23 Consistent with Preannouncement; Aiming for $100M of Sales in 2025'

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

February 28, 2024 4:01 PM EST

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.

Recent Business Highlights

Obtained final Medicare coverage determination for its NeXT Dx® comprehensive tumor genomic profiling test, providing access for the 66 million Medicare and Medicare Advantage beneficiaries Entered into a strategic partnership with Tempus AI, Inc. (formerly known as Tempus Labs) to co-commercialize NeXT Personal® Dx in... More